Epigenetics is referred to as the study of heritable and reversible forms of gene regulation which are not dependent on the DNA sequence. This regulation basically includes DNA methylation and also histone methylation, ubiquitination, acetylation, and phosphorylation. Epigenetic drugs which are designed to fight cancer might also be used against many of the viruses. Epigenetics Drugs market is expected to witness moderate growth during the forecast period, which is owing to the rise in the epigenetic drug discovery. Furthermore, a surge in the prevalence of cancer and some of the technological advancements in the epigenetics research are anticipated to augmented the market growth
- Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions
- Huge Amounts of Investment
- Advancement In the Screening Tools
- The Genericization Of Major Drugs
Growing Technological Advancement Related To Product Market
Players Covered in the Study are:
Astex Pharmaceuticals Inc. (United Kingdom), Cellcentric Ltd. (United States), Celleron Therapeutics Ltd. (United States), Celgene Corporation (United States), Epigentek Group Inc. (United States), Eisai Co. Ltd. (Japan), Epizyme, Inc. (United States), Illumina Inc. (United States), Mdxhealth (Belgium) and Merck & Company Inc. (United States)
The Global Epigenetics Drugs market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.
MDxHealth signs partnership with LifeLabs to make SelectMDx available in Canada. LifeLabs is a leading Canadian company that performs over 100 million laboratory tests per year to help diagnose, treat, monitor and prevent diseases, supporting over 19 million patient visits annually
List of players that can be included in the study on immediate basis are Novartis International AG (Switzerland), Oncolys Biopharma Inc. (Japan), Pharmacyclics, Inc. (United States) and Promega Corporation (United States).